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The treatment of patients with coronary artery disease
continues to evolve. This evolution proceeds in fits and
starts — rapid changes interspersed with plateaus. Upon
reaching each plateau, there is the temptation to believe that
it is now time to address the question, once and for all, of
what is the best treatment strategy for patients. Such an
approach has some disadvantages: the procedure is
continually evolving; yardsticks (endpoints) in use also
continue to change; and patients (and their expectations)
continue to change. These caveats are not meant to
denigrate randomized clinical trials because they remain the
key to evidence-based medicine.
Treatment strategies
The three components of current treatment strategy —
medical therapy, surgical revascularization, and percutaneous
coronary intervention (PCI) — are all changing. Medical
therapy, however, should remain the mainstay. Intensive risk-
factor modification with medical therapy is essential,
irrespective of whether it is the sole therapy or whether the
patient requires revascularization.
Surgical revascularization has also changed [1–5]. This
change has arguably (but probably) been the result of the
competition from the “newer kid on the block” — PCI. Even
surgeons have finally embraced the ideal of “less
invasiveness” with new approaches such as the minimally
invasive “beating heart surgery”.
However, the field that has changed the most is PCI, with the
introduction of stents (previously only used in few patients up
to the mid-1990s, but now in approximately 90% of cases)
[6–9], threnopyndines [10–12], and glycoprotein (GP) IIb/IIIa
inhibitors [13–17]. It has been documented to reduce
enzyme elevation post-procedure, and may improve harder
endpoints in other patient groups.
Trials comparing therapies
The article by Bhatt and Topol, in this issue of Current
Controlled Trials in Cardiovascular Medicine, reviews the
latest trials comparing stenting with bypass surgery, for the
treatment of multivessel coronary disease [18]. Both the
Arterial Revascularisation Therapy Study (ARTS) and the
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Abstract
The treatment of patients with coronary artery disease continues to evolve; all three strategies —
medical therapy, surgical revascularization, and percutaneous coronary intervention — have changed.
Medical therapy with intense risk-factor modification and treatment with a statin, aspirin, and
angiotensin-converting enzyme (ACE) inhibitors, should be used unless contraindicated. Surgical
therapy has also changed with the introduction of minimally invasive, beating heart surgery.
Percutaneous coronary intervention has perhaps changed the most radically with adjunctive therapy —
glycoprotein IIb/IIIa inhibitors, thienopyridines, and reliance on stent implantation. The future, with new
distal protection devices and drug-coated stents, should continue to see increased numbers of
patients who can benefit from percutaneous intervention.
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Stent or Surgery (SoS) trial, are important additions [2–3].
However, as yet, we have details only for ARTS, as the SoS
trial has only recently been presented at the 2001 American
College of Cardiology Scientific Sessions and has not yet
been published.
For the ARTS trial, we know that one-year mortality rates and
the combined endpoint (death, myocardial infarction, and
cerebrovascular accident) were similar [2]. These trends
were also seen after two years of follow-up. Follow-up target
vessel revascularization rates remain higher in the stent
group, but the gap between the stenting and surgery has
closed dramatically from previously published trials of
percutaneous coronary intervention versus surgery.
In the Bypass Angioplasty Revascularization Investigation
(BARI), diabetic patients treated with coronary bypass graft
surgery (CABG) had a better mortality at two years [1]. There
were other important differences in the ARTS trial, namely,
creatinine kinase (CK) elevation was more than twice as
frequent in the surgical group (12.6% versus 6.2%,
P < 0.001). Of interest, elevated level of CK-MB was the
main predictor of a poor outcome in the surgical group, but
not in the PCI group in which the main factor for a poor
outcome was the presence of diabetes mellitus. The authors
concluded that, “coronary stenting for multivessel disease is
less expensive than bypass surgery and offers the same
degree of protection against death, stroke, and myocardial
infarction; however, stenting was associated with a greater
need for repeat revascularization”.
Details of the SoS trial remain unpublished, but are hopefully
in press at this time. The investigators have showed a
mortality disparity with the PCI group having increased
mortality. This imbalance in mortality was apparently related
to malignancy and, as Bhatt and Topol suggest, “play of
chance is the likeliest explanation for this finding” [18].
Which is the winner?
Bhatt and Topol speculate on “the winner” of the controversy
[18]. This is difficult to determine, as it depends on the
“scorecard” system used to define “winning.” If the scorecard
endpoint were death or myocardial infarction, at least with
nondiabetic patients, the answer would be a toss-up (it could
go either way). The ten-year follow-up data on nondiabetic
patients from the BARI trial show almost identical event-free
survival in both surgery and percutaneous transluminary
coronary angioplasty (PTCA), using this endpoint. If,
however, the scorecard endpoint is the avoidance of t he
potentially debilitating effects of central nervous system
function disturbance, post revascularization with dramatic
decrease in neurocognitive function, then PCI is the clear
winner [19]. This is, in part, because there is considerable
evidence of neurocognitive changes after CABG, but it has
not been assessed after PCI; the SoS trial may help with this.
On the other hand, if the scorecard is avoidance of a repeat
procedure, such as repeat PCI, then CABG is the winner.
Patient expectation plays a major role here.
Do GP IIb/IIa inhibitors improve outcome?
There are other issues with these trials; as Bhatt and Topol
discuss, GP IIb/IIIa inhibitors were used infrequently [18].
These agents have been studied intensively in the setting of
acute coronary syndromes as well as PCI, and have been
found to dramatically decrease periprocedural cardiac
enzyme elevation. Whether this would have made a large
difference in the follow-up of these patients with multivessel
disease, is as yet undetermined. In diabetic patients, [15–17]
there is longer-term evidence that mortality rates may be
improved with GP IIb/IIIa agents, although this has not been
specifically studied in a randomized trial. The lower use of
GP IIb/IIIa agents, mirrors the practice in Europe where these
agents are not used routinely — primarily because of cost.
There are other advances which these trials also do not take
into consideration because these were not either available or
not widely used as the standard of care.
There is great interest in the use of distal protection devices,
which may improve the outcome of PCI and decrease
embolization [20]. Similarly, drug-coated stents appear to
dramatically decrease restenosis rates, and if the forthcoming
trials substantiate the early results, they will revolutionize the
field [21].
Conclusion
Bhatt and Topol wondered if the battle was over. I believe
entirely that it is not. There have been dramatic changes in
interventional cardiology. GP IIb/IIIa agents have been
introduced which will be used to prevent lesions and
periprocedural infarction in higher risk patients, and drug-
coated stents may prevent angiographic and clinical
restenosis. This will dramatically improve the early and
longer-term success rate of PCI. Surgery, however, will
remain an excellent treatment strategy, at least for patients
who are not candidates for percutaneous intervention and
probably for the diabetic patients (particularly those with
advanced multivessel disease and impaired left ventricular
function). For the majority of patients who could have either
PCI or surgery, the less invasive approach with percutaneous
intervention, will become the standard.
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